$3.70
-0.01000-0.27%
At close: -
$3.70
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Cytek Biosciences Analyst Ratings and Price Targets | NASDAQ:CTKB | Benzinga
Cytek Biosciences Inc has a consensus price target of $7.75 based on the ratings of 5 analysts. The high is $10 issued by Goldman Sachs on February 29, 2024. The low is $6 issued by Stephens & Co. on March 19, 2025. The 3 most-recent analyst ratings were released by Stephens & Co., Piper Sandler, and Piper Sandler on March 19, 2025, March 4, 2025, and November 11, 2024, respectively. With an average price target of $7.5 between Stephens & Co., Piper Sandler, and Piper Sandler, there's an implied 102.70% upside for Cytek Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stephens & Co.
Piper Sandler
Goldman Sachs
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Cytek Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/19/2025 | Buy Now | 62.16% | Stephens & Co. | Mason Carrico39% | $6 → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 03/04/2025 | Buy Now | 116.22% | Piper Sandler | David Westenberg59% | $8.5 → $8 | Maintains | Overweight | Get Alert |
| 11/11/2024 | Buy Now | 129.73% | Piper Sandler | David Westenberg59% | $8 → $8.5 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 116.22% | Piper Sandler | David Westenberg59% | $8.5 → $8 | Maintains | Overweight | Get Alert |
| 05/13/2024 | Buy Now | 129.73% | Piper Sandler | David Westenberg59% | $10 → $8.5 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 170.27% | Piper Sandler | David Westenberg59% | $11 → $10 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 170.27% | Goldman Sachs | Matthew Sykes66% | $9 → $10 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | 143.24% | Stephens & Co. | Mason Carrico39% | → $9 | Initiates | → Overweight | Get Alert |
| 11/09/2023 | Buy Now | 89.19% | Morgan Stanley | Tejas Savant50% | $8 → $7 | Maintains | Equal-Weight | Get Alert |
| 10/24/2023 | Buy Now | 116.22% | Morgan Stanley | Tejas Savant50% | $13 → $8 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 170.27% | Piper Sandler | David Westenberg59% | $15 → $10 | Maintains | Overweight | Get Alert |
| 07/19/2023 | Buy Now | — | Raymond James | Andrew Cooper55% | — | Initiates | → Market Perform | Get Alert |
| 05/11/2023 | Buy Now | 251.35% | Morgan Stanley | Tejas Savant50% | $14 → $13 | Maintains | Equal-Weight | Get Alert |
| 05/10/2023 | Buy Now | 224.32% | Goldman Sachs | Matthew Sykes66% | $14 → $12 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 305.41% | Piper Sandler | David Westenberg59% | $18 → $15 | Maintains | Overweight | Get Alert |
| 03/02/2023 | Buy Now | 278.38% | Morgan Stanley | Tejas Savant50% | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 03/02/2023 | Buy Now | 278.38% | Goldman Sachs | Matthew Sykes66% | $16 → $14 | Maintains | Buy | Get Alert |
| 08/18/2022 | Buy Now | 332.43% | Piper Sandler | David Westenberg59% | $12 → $16 | Maintains | Overweight | Get Alert |
| 08/12/2022 | Buy Now | 305.41% | Morgan Stanley | Tejas Savant50% | $11 → $15 | Maintains | Equal-Weight | Get Alert |
| 08/11/2022 | Buy Now | 359.46% | Goldman Sachs | Matthew Sykes66% | $15 → $17 | Maintains | Buy | Get Alert |
| 07/14/2022 | Buy Now | 305.41% | Goldman Sachs | Matthew Sykes66% | $12 → $15 | Maintains | Buy | Get Alert |
| 05/16/2022 | Buy Now | 224.32% | Piper Sandler | David Westenberg59% | $17 → $12 | Maintains | Overweight | Get Alert |
| 05/13/2022 | Buy Now | 197.3% | Morgan Stanley | Tejas Savant50% | $18 → $11 | Maintains | Equal-Weight | Get Alert |
| 05/12/2022 | Buy Now | 224.32% | Goldman Sachs | Matthew Sykes66% | $14 → $12 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Cytek Biosciences (CTKB) stock?
The latest price target for Cytek Biosciences (NASDAQ:CTKB) was reported by Stephens & Co. on March 19, 2025. The analyst firm set a price target for $6.00 expecting CTKB to rise to within 12 months (a possible 62.16% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cytek Biosciences (CTKB)?
The latest analyst rating for Cytek Biosciences (NASDAQ:CTKB) was provided by Stephens & Co., and Cytek Biosciences reiterated their overweight rating.
When was the last upgrade for Cytek Biosciences (CTKB)?
There is no last upgrade for Cytek Biosciences
When was the last downgrade for Cytek Biosciences (CTKB)?
There is no last downgrade for Cytek Biosciences.
When is the next analyst rating going to be posted or updated for Cytek Biosciences (CTKB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on March 19, 2025 so you should expect the next rating to be made available sometime around March 19, 2026.
Is the Analyst Rating Cytek Biosciences (CTKB) correct?
While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a reiterated with a price target of $6.00 to $6.00. The current price Cytek Biosciences (CTKB) is trading at is $3.70, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
